Genomics and proteomics: Application of novel technology to early detection and prevention of cancer

Cancer Detection and Prevention

Volumn 26, Issue 4, 2002, Pages 249-255

  Michener, Chad M ^a   Ardekani, Ali M ^a   Petricoin III, Emmanuel F ^a   Liotta, Lance A ^a   Kohn, Elise C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; Laser capture microdissection; Molecular targeted therapies

Indexed keywords

GENOMICS; HUMAN; METHODOLOGY; NEOPLASM; PROTEOMICS; REVIEW;

GENOMICS; HUMANS; NEOPLASMS; PROTEOMICS;

EID: 0036996552     PISSN: 0361090X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0361-090X(02)00092-2     Document Type: Review

References (57)

1. Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, et al. The sequence of the human genome. Science 2001;291:1304-51.
2. Lander ES, Linton LM, Birren B, Nusbaum C. Zody MC, et al. Initial sequencing and analysis of the human genome. Nature 2001;409:860-921.
3. Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, et al. Laser capture microdissection. Science 1996;274:998-1001.
4. Bonner RF, Emmert-Buck MR, Cole K, Pohida T, Chuaqui RF, et al. Laser capture microdissection: molecular analysis of tissue. Science 1997;278:1481-3.
5. Paweletz CP, Charboneau L, Bichsel VE, Simone NL, Chen T, et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 2001;20:1981-9.
6. Liotta LA, Kohn EC, Petricoin III EF. Clinical proteomics: personalized molecular medicine. JAMA 2001;286:2211-4.
7. Petricoin III EF. Ardekani AM, Hitt BA, Levine PJ, Steinberg SM, et al. Proteomic patterns in sera detect early stage ovarian cancer. Lancet 2002;359:572-7.
8. Brinton LA, Hoover RN. Epidemiology of gynecologic cancers. In: Hoskins WJ, Perez CA, Young RC, editors. Principles and practice of gynecology, 3rd ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 3-27.
9. SEER Cancer Statistics Review: 1973-1991. In: Ries LAG, Miller BA, Hankey BE Kosary CL, Harris A, Edwards BK, editors. Bethesda, MD: National Cancer Institute; 1994. p. 136-44.
10. Hatch KD, Schneider A, Abdel-Nour MW. An evaluation of human papillomavirus testing for intermediate- and high-risk types as triage before colposcopy. Am J Obstet Gynecol 1995;172:1150-5.
11. Bernard HU, Chan SY, Manos MM, Ong CK, Villa LL, et al. Identification and assessment of known and novel human papillomaviruses by polymerase chain reaction amplification, restriction fragment length polymorphisms, nucleotide sequence, and phylogenetic algorithms. J Infect Dis 1994;170:1077-85.
12. Bauer HM, Ting Y, Greer CE, Chambers JC, Tashiro CJ, et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method. JAMA 1991;265:472-7.
13. Baselga J, Norton L, Albanell J. Kim YM, Mendelsohn J. Recombinant humanized anti-HER-2 antibody (Herceptin) enhances the anti-tumor activity of paclitaxel and doxorubicin against HER-2/neu overexpressing human breast cancer xenografts. Cancer Res 1998;58:2825-31.
14. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER-2/neu monoclonal antibody plus cisplatin in patients with HER-2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659-71.
15. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, et al. Safety and efficacy of imatinib (ST1571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001:358:1421-3.
16. Franzen B, Hirano T, Okuzawa K, Uryu K, Alaiya AA, et al. Sample preparation of human tumors prior to two-dimensional electrophoresis of proteins. Electrophoresis 1995;16:1087-9.
17. Zvibel I, Brill S, Papa M, Halpern Z. Hepatocyte-derived soluble factors regulate proliferation and autocrine growth factor expression in colon cancer cell lines of varying liver-colonizing capability. Tumour Biol 2000;21:187-96.
18. Bemis LT, Schedin P. Reproductive state of rat mammary gland stroma modulates human breast cancer cell migration and invasion. Cancer Res 2000;60:3414-8.
19. Chung LW. Fibroblasts are critical determinants in prostatic cancer growth and dissemination. Cancer Metastasis Rev 1991;10:263-74 [Review].
20. Berger SJ, DeVries GW, Carter JG, Schulz DW. Passonneau PN, et al. The distribution of the components of the cyclic GMP cycle in retina. J Biol Chem 1980;255:3128-33.
21. Radford DM, Fair K, Thompson AM, Ritter JH, Holt M, et al. Allelic loss on a chromosome 17 in ductal carcinoma in situ of the breast. Cancer Res 1983;53:2947-9.
22. Liotta LA, Kohn EC. The microenvironment of the tumor-host interface. Nature 2001;411:375-9.
23. Fend F, Emmert-Buck MR, Chuaqu IR, Cole K, Lee J, et al. Immuno-LCM: laser capture microdissection of immunostained frozen sections for mRNA analysis. Am J Pathol 1999;154:61-6.
24. Jones MB, Krutzsch H, Shu H, Zhao Y, Liotta LA, et al. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2002:2:76-84.
25. Ornstein DK, Gillespie JW, Paweletz CP, Duray PH, Herring J, et al. Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis 2000;21:2235-42.
26. Geisler JP, Hatterman-Zogg MA, Rathe JA, Buller RE. Frequency of BRCA1 dysfunction in ovarian cancer. J Natl Cancer Inst 2002;94:61-7.
27. Sobol H, Benziane A. Kerangueven F, Yin L, Noguchi T, et al. Genome-wide search for loss of heterozygosity in Burkitt lymphoma cell lines. Genes Chromosomes Cancer 2002;33:217-24.
28. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999;21:99-102.
29. Hui AB, Lo KW, Teo PM, To KF, Huang DP. Genome wide detection of oncogene amplifications in nasopharyngeal carcinoma by array-based comparative genomic hybridization. Int J Oncol 2002;20:467-73.
30. Fodor SP, Rava RP, Huang XC, Pease AC, Holmes CP, et al. Multiplexed biochemical assays with biological chips. Nature 1993;364:555-6.
31. DeRisi J, Penland L, Brown PO, Bittner ML, Meltzer PS, et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet 1996;14:457-60.
32. Zhang L, Zhou W, Velculescu VE, Kern SE, Hruban RH, et al. Gene expression profiles in normal and cancer cells. Science 1997;276:1268-72.
33. Velculescu VE, Zhang L, Vogelstein B, Kinzler KW. Serial analysis of gene expression. Science 1995;270:484-7.
34. MacBeath G, Schreiber SL. Printing proteins as microarrays for high-throughput function determination. Science 2000;289:1760-3.
35. Slamon DJ. Godolphin W, Jones LA, Holt JA, Wong SG, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989:244:707-12.
36. Bur ME, Perlman C, Edelmann L, Fey E, Rose PG. p53 expression in neoplasms of the uterine corpus. Am J Clin Pathol 1992;98:81-7.
37. Hale RJ, Buckley CH, Gullick WJ, Fox H, Williams J, et al. Prognostic value of epidermal growth factor receptor expression in cervical carcinoma. J Clin Pathol 1993;46:149-53.
38. Kwiatkowski DJ, Harpole Jr DH, Godleski J, Herndon II JE, Shieh DB, et al. Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. J Clin Oncol 1998;16:2468-77.
39. Chung YL, Sheu ML, Yang SC, Lin CH, Yen SH. Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer. Int J Cancer 2002;97:306-12.
40. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 1989;320:479-84.
41. Lueking A, Horn M, Eickhoff H. Bussow K, Lehrach H, et al. Protein microarrays for gene expression and antibody screening. Anal Biochem 1999;270:103-11.
42. Vasiliskov AV, Timofeev EN, Surzhikov SA, Drobyshev AL. Shick VV, et al. Fabrication of microarray of gel-immobilized compounds on a chip by copolymerization. Biotechniques 1999;27:592-4, 592-606.
43. Emmert-Buck MR, Strausberg RL, Krizman DB, Bonaldo MF, Bonner RF, et al. Molecular profiling of clinical tissues specimens: feasibility and applications. J Mol Diagn 2000;2:60-6.
44. Paweletz CP, Ornstein DK, Roth MJ, Bichsel VE, Gillespie JW, et al. Loss of annexin-1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. Cancer Res 2000;60:6293-7.
45. Herbert BR, Sanchez JC, Bini L. Two-dimensional electrophoresis: the state of the art and future directions. In: Wilkins MR, Williams KL, Appel RD, Hochstrasser DF, editors. Proteome research: new frontiers in functional genomics. New York: Springer; 1997. p. 13-33.
46. Paweletz CP, Gillespie JW, Ornstein DK, Simone NL, Brown MR, et al, Rapid protein display profiling of cancer progression directly from human tissue using a protein biochip. Drug Dev Res 2000:49:34-42.
47. Richter R, Schulz-Knappe P, Schrader M, Standker L, Jurgens M, et al. Composition of the peptide fraction in human blood plasma: database of circulating human peptides. J Chromatogr B Biomed Sci Appl 1999;726:25-35.
48. Jacobs IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet 1999;353:1207-10.
49. Jacobs I, Davies AP, Bridges J, Stabile I, Fay T, et al. Prevalence screening for ovarian cancer in post-menopausal women by CA 125 measurement and ultrasonography. BMJ 1993;306:1030-4.
50. DePriest PD, Gallion HH, Pavlik EJ, Kryscio RJ, van Nagell Jr JR. Transvaginal sonography as a screening method for the detection of early ovarian cancer. Gynecol Oncol 1997;65:408-14.
51. van Nagell Jr JR, DePriest PD, Reedy MB, Gallion HH, Ueland FR, et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol 2000;77:350-6.
52. Cohen LS, Escobar PF, Scharm C, Glimco B, Fishman DA. Three-dimensional power doppler ultrasound improves the diagnostic accuracy for ovarian cancer prediction. Gynecol Oncol 2001;82:40-8.
53. Bast Jr RC, Klug TL, St John E, Jenison E, Niloff JM, et al. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-7.
54. Ozols RF, Rubin SC, Thomas GM, Robboy SJ. Epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC, editors. Principles and practice of gynecology, 3rd ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 981-1057.
55. van Haaften-Day C, Shen Y, Xu F, Yu Y, Berchuck A, et al. OVX1, macrophage-colony stimulating factor, and CA 125 II as tumor markers for epithelial ovarian carcinoma: a critical appraisal. Cancer Metastasis Rev 2001;92:2837-44.
56. Xu Y, Shen Z, Wiper DW, Wu M, Morton RE, et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 1998;280:719-23.
57. van Nagell Jr JR, Gallion HH, Pavlik EJ, DePriest PD. Ovarian cancer screening. Cancer Metastasis Rev 1995;76:2086-91.